| __timestamp | Neurocrine Biosciences, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 5078000000 |
| Thursday, January 1, 2015 | 32480000 | 4717000000 |
| Friday, January 1, 2016 | 68081000 | 5096000000 |
| Sunday, January 1, 2017 | 169906000 | 4986000000 |
| Monday, January 1, 2018 | 248932000 | 4214000000 |
| Tuesday, January 1, 2019 | 354100000 | 3806000000 |
| Wednesday, January 1, 2020 | 433300000 | 3671000000 |
| Friday, January 1, 2021 | 583300000 | 3528000000 |
| Saturday, January 1, 2022 | 752700000 | 3445000000 |
| Sunday, January 1, 2023 | 887600000 | 3498000000 |
| Monday, January 1, 2024 | 1007200000 | 3702000000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, effective cost management is crucial. Over the past decade, Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Neurocrine Biosciences, Inc. saw a staggering 4,800% increase in SG&A expenses, reflecting its aggressive growth and expansion strategy. In contrast, Teva Pharmaceutical Industries Limited experienced a 31% reduction, indicating a strategic shift towards cost optimization.
This divergence highlights the different paths companies can take in response to market pressures and opportunities. While Neurocrine's rising expenses suggest a focus on scaling operations, Teva's cost-cutting measures may be aimed at maintaining profitability amidst industry challenges.
Understanding these trends provides valuable insights into the financial health and strategic priorities of these pharmaceutical giants.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared